CF is a genetic condition affecting more than 10 800 people in the UK. CF is caused by a mutation in the gene cystic fibrosis trans membrane conductance regulator (CFTR).Prior to the licensing of Ivacaftor, standard treatment for CF was to treat symptoms associated with CF but not the underlying cause. Ivacaftor targets the CFTR gene. Ivacaftor is funded by NHS England, if criteria outlined in the clinical commissioning policy is followed.1,2Aim
Ensure Ivacaftor is prescribed in adherence to guidance documented in the Clinical Commissioning Policy: Ivacaftor for CF (2012) and Clinical Commissioning Policy: Ivacaftor for children aged 2–5 years with CF, named mutations (2016).1,2Standards
100% of Ivacaftor prescriptions will be for patients:Standards
100% of patients will receive a follow up sweat test/lung function test (6 years and older) at:Method
Retrospective study investigated the prescribing of Ivacaftor in CF patients from March 2012 – June 2017 at an NHS trust. Ethics approval not required. List of patients prescribed Ivacaftor was obtained from the CF team. Patient age, mutation type, treatment start dates, lung function test results were obtained from medical notes. Dates and results of sweat tests were obtained from Sunquest ICE Desktop (electronic patient reporting system). Data analysed using Microsoft excel.Results
Eight patients prescribed Ivacaftor at the NHS trust between March 2012–June 2017. Baseline sweat chloride data unavailable for one patient who was previously part of a clinical trial. This patient was excluded from standard 2, however maintained for the other standards as his annual sweat data was available. One patient was excluded from standard 3(a), five patients excluded from standard 3 (b), (c) as they had not yet reached this stage of treatment. Standard 4 was not evaluated as all patients to date were responding to treatment. Overall, all standards were completely met with a result of 100%.Discussion and conclusion
Standards were completely met; highlighting a robust system ensuring all appropriate testing is adhered to, as failure to comply with the criteria in the clinical commissioning policy may contribute to pressure within the trust’s budget. Treatment response can also be appropriately determined.